Developing a novel class of drugs to treat life‐threatening systemic fungal infections.
Developing a novel class of drugs to treat life‐threatening systemic fungal infections.
Sectors
Healthcare
Life Sciences
First Invested
2015
Early
Company Status
Acquired
Acquired by Pfizer
Associated Team
Edward Mathers
About
Team
Portfolio
Insights
About
Team
Portfolio
Insights